A Study of MORAb-202 in Participants With Solid Tumors

  • STATUS
    Recruiting
  • End date
    Dec 31, 2021
  • participants needed
    120
  • sponsor
    Eisai Inc.
Updated on 1 August 2021
Investigator
Inquiry Service
Primary Contact
Eisai Trial Site 6 (0.0 mi away) Contact
+9 other location
platelet count
cancer
measurable disease
carcinoma
growth factor
endocrine therapy
lung cancer
metastasis
neutrophil count
hormone therapy
liver metastasis
blood transfusion
folic acid
cancer treatment
solid tumor
targeted therapy
platelet transfusion
endometrial carcinoma

Summary

The primary objective of this study is to evaluate the tolerability and safety profile of MORAb-202 in participants with solid tumors.

Details
Condition Solid Tumors, Solid Neoplasm, Solid Tumour
Treatment MORAb-202
Clinical Study IdentifierNCT03386942
SponsorEisai Inc.
Last Modified on1 August 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note